KMB Kimberly-Clark

Kimberly-Clark manufactures personal care and tissue products under brands including Huggies, Kleenex, Scott, and Kotex, sold in over 175 countries. Sector: Consumer Staples.

Kimberly-Clark (KMB) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

On the question of capital productivity, ROIC is 18.31%, WACC is 5.66%, and the economic spread is 12.65%. On balance, the economic spread is positive and meaningful, suggesting the company are building rather than eroding intrinsic value. Supporting metrics show ROE at 146.87% and ROA at 10.85%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

On a multiple basis, the company trades at trailing P/E of 17.81, forward P/E of 12.70, PEG of 3.41. Forward P/E is below trailing by a moderate margin, pointing to modest earnings expectations that support the current valuation without relying on outsized growth. The PEG reading is high enough to suggest the market is attributing significant optionality or quality premium to the company's underlying businesses. The company carries an aggregate current ratio of 0.75, pointing to constrained near-term balance sheet coverage. The valuation setup is broadly consistent with a market that is pricing growth without being reckless about it — a balanced but not cautious stance.

The margin stack reads as follows: gross margin sits at 36.49%, operating margin at 15.08%, and free cash flow margin at 9.74%. Gross margins are in the moderate range, typical of sectors where direct costs consume a larger share of revenue. The company's operating margins are solid, pointing to overhead management that appears to be a relative strength. FCF margins are in a reasonable range, though there is room for improvement in how efficiently revenues convert to free cash. The profile is not weak, but it is uneven enough that execution and cost control remain central to the forward case.

Where growth and expectations intersect, the estimated 12-month price change of 24.61%, where analyst assumptions support a moderate upside case if execution remains steady, while TTM revenue growth of -10.52% pointing to declining revenues that, if sustained, could pressure margins and forward estimates. The projected 12-month EPS growth rate of 40.3% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. Both signals are useful lenses, but they tend to diverge most sharply near inflection points in both business fundamentals and market sentiment. The durability of both the operating trend and analyst optimism will determine whether the current setup translates into measurable near-term returns. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The overall evidence base is constructive, with more signals pointing up than down and no obvious structural impairment to the forward case.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.